84745-95-9

Usage

Uses

Used in Pharmaceutical Industry:
Eriocalyxin B is used as a potential therapeutic agent for cancer treatment due to its ability to induce apoptosis in cancer cells and inhibit metastasis and angiogenesis. Its anti-cancer properties make it a promising candidate for the development of new cancer therapies.
Used in Anti-inflammatory Applications:
Eriocalyxin B is used as an anti-inflammatory agent for the management of inflammatory conditions such as arthritis. Its anti-inflammatory properties help alleviate symptoms and reduce inflammation in affected joints.
Used in Antimalarial Applications:
Eriocalyxin B is used as an antimalarial agent by targeting the Plasmodium parasite responsible for causing malaria. Its anti-malarial activity makes it a potential candidate for the development of new antimalarial drugs.

Relevant academic research and scientific papers

Scalable synthesis enabling multilevel bio-evaluations of natural products for discovery of lead compounds

Challenges in the development of anti-cancer chemotherapeutics continue to exist, particularly with respect to adverse effects and development of resistance, underlining the need for novel drugs with good safety profiles. Natural products have proven to be a fertile ground for exploitation, and development of anti-cancer drugs from structurally complex natural products holds promise. Unfortunately, this approach is often hindered by low isolation yields and limited information from preliminary cell-based assays. Here we report a concise and scalable synthesis of a series of low-Abundance Isodon diterpenoids (a large class of natural products with over 1000 members isolated from the herbs of genus Isodon, which are well-known folk medicines for the treatment of inflammation and cancer), including eriocalyxin B, neolaxiflorin L and xerophilusin I. These scalable syntheses enable multilevel bio-evaluation of the natural products, in which we identify neolaxiflorin L as a promising anti-cancer drug candidate.